NCT00789399.

Trial name or title	"A study of the efficacy of preventive dosing of fondaparinux sodium versus placebo for the prevention of venous thromboembolism (VTE) in patients undergoing coronary bypass surgery receiving routine mechanical prophylaxis"
Methods	Prospective, single‐centre, phase II randomised study, single‐blind (investigator)
Participants	Consecutive patients aged 18 years or older undergoing isolated or redo isolated CABG
Interventions	Fondaparinux (2.5 mg subcutaneous daily) starting 12 +/‐ 2 hours post‐wound closure or the following day in the morning (at the discretion of the cardiothoracic surgeon). The second dose would be administered 24 hours later and the dosing will then be once a day The group randomised to placebo will receive subcutaneous equivalent volume of isotonic saline at the same time points described above Patients will receive fondaparinux or placebo for a total of 3 to 9 days post CABG with day 1 being the day of surgery. The drug will be discontinued if the patient is discharged before day 9. If the patient stays for more than 9 days inside hospital, a duplex would be obtained per protocol and further DVT prevention measures would be instituted per the discretion of treating physician Both groups will receive routine mechanical prophylaxis as determined by the treating physicians
Outcomes	Primary outcome: rate of asymptomatic proximal DVT Secondary outcome: asymptomatic distal DVT
Starting date	October 2009
Contact information	Cynthia Deitrick (cdeitrick@prairieresearch.com). Principal investigator: Raghu Kolluri
Notes	ClinicalTrials.gov identifier: NCT00789399